IDO1 and melanoma: However, phase III clinical trials (NCT02752074/ECHO-301/KEYNOTE-252) combining epacadostat (that specifically targets IDO) with pembrolizumab (anti–PD-1) in advanced melanoma resulted in no significant improvement in patient outcomes (55, 56).